- Trials with a EudraCT protocol (52)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (23)
52 result(s) found for: D4.
Displaying page 1 of 3.
EudraCT Number: 2011-004609-26 | Sponsor Protocol Number: Methadone-FR-CL0390 | Start Date*: 2011-12-02 | |||||||||||
Sponsor Name:Laboratoires Bouchara-Recordati | |||||||||||||
Full Title: Evaluation of the efficacy and safety of two methadone titration methods for the treatment of cancer-related pain with inadequate pain relief or intolerable side effects when treated with level 3 o... | |||||||||||||
Medical condition: Treatment of cancer-related-pain in patients with inadequate pain relief or intolerable side effects when treated with level 3 opioid. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004469-11 | Sponsor Protocol Number: PP-SA-001 | Start Date*: 2022-01-11 |
Sponsor Name:PHERECYDES PHARMA | ||
Full Title: PhagoDAIR I: A Phase I/II Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus ... | ||
Medical condition: knee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SAT | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002492-11 | Sponsor Protocol Number: PRECESTO | Start Date*: 2023-09-13 | |||||||||||
Sponsor Name:NFL BIOSCIENCES SA | |||||||||||||
Full Title: Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes | |||||||||||||
Medical condition: Tobacco addiction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002319-41 | Sponsor Protocol Number: HULP-VIR-2014-01 | Start Date*: 2015-05-11 | |||||||||||
Sponsor Name:Ana Boto de los Bueis | |||||||||||||
Full Title: Clinical and virologic assesment of two therapeutic options: antiviral Ganciclovir 0.15% ophthalmic gel and physiologic saline solution 0.9% used in patients with acute adenoviral conjuntivitis. | |||||||||||||
Medical condition: Acute adenoviral conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003994-80 | Sponsor Protocol Number: ET18-270 | Start Date*: 2019-10-03 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases | |||||||||||||
Medical condition: Brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000341-13 | Sponsor Protocol Number: OTV.PRE.01 | Start Date*: 2012-08-28 | ||||||||||||||||
Sponsor Name:Weber & Weber GmbH & Co. KG | ||||||||||||||||||
Full Title: Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Grou... | ||||||||||||||||||
Medical condition: recurrent acute otitis media | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002711-83 | Sponsor Protocol Number: 09-2004 PaedonkoChar | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:HELIXOR Heilmittel GmbH & Co.KG | |||||||||||||
Full Title: Evaluation of anthroposophic supportive medicine on treatment-related toxicity in children receiving cancer therapy | |||||||||||||
Medical condition: The trial will be open to patients being treated according to current protocols for solid tumors and leukemias/lymphomas of the German Society for Paediatric Oncology and Haematology (GPOH) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000907-29 | Sponsor Protocol Number: SHDE-1 | Start Date*: 2014-08-25 |
Sponsor Name:Hevert-Arzneimittel GmbH & Co. KG | ||
Full Title: Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute, uncomplicated rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, paral... | ||
Medical condition: acute, uncomplicated rhinosinusitis | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004840-36 | Sponsor Protocol Number: CHDE-1 | Start Date*: 2015-09-03 |
Sponsor Name:Hevert-Arzneimittel GmbH & Co. KG | ||
Full Title: Proof of effectiveness of Calmvalera Hevert using qantitative measurement of electrical brain activity on 24 subjects during image and video-mediated cognitive and emotional stress. A double-blind,... | ||
Medical condition: Subjects who suffer from exam nerves | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001759-38 | Sponsor Protocol Number: K675 | Start Date*: 2019-12-04 |
Sponsor Name:Ruprecht-Karls University Heidelberg Medical Faculty, University Hospital represented in law by its commercial director | ||
Full Title: Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects | ||
Medical condition: 20 children with non-cyanotic congenital heart defects especially atrial septal defects (ASD) and ventricular septal defects (VSD) in admitted to the paediatric cardiology wards will be included. T... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004423-20 | Sponsor Protocol Number: V00498TA301 | Start Date*: 2013-01-10 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: STUDY OF EFFICACY AND SAFETY OF V0498 VERSUS PLACEBO IN ACUTE SORE THROAT PAIN | |||||||||||||
Medical condition: Acute sore throat | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) LV (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001897-13 | Sponsor Protocol Number: ITM-LET-01 | Start Date*: 2017-08-22 | |||||||||||
Sponsor Name:ITM Solucin GmbH | |||||||||||||
Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar... | |||||||||||||
Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003157-55 | Sponsor Protocol Number: EF-39 | Start Date*: 2023-03-30 | |||||||||||
Sponsor Name:Novocure GmbH | |||||||||||||
Full Title: PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal ... | |||||||||||||
Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001139-98 | Sponsor Protocol Number: IC2021-07 | Start Date*: 2022-06-13 | ||||||||||||||||
Sponsor Name:Institut Curie | ||||||||||||||||||
Full Title: Opioid-Free versus Opioid-Based Anaesthesia for secondary free-flap reconstruction surgery of the breast: A phase III multicentric randomized controlled study | ||||||||||||||||||
Medical condition: Anaesthesia during secondary free flap reconstruction surgery of the breast. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001242-25 | Sponsor Protocol Number: BBT120126032001 | Start Date*: 2017-02-07 | ||||||||||||||||
Sponsor Name:Blueberry Therapeutics Ltd. | ||||||||||||||||||
Full Title: An Early Phase Development, Partly Blinded, Positive and Vehicle Controlled, Randomized, Non-inferiority Investigation of the Pharmacokinetics, Safety and Efficacy of BB2603 Cutaneous Hand-Pump Spr... | ||||||||||||||||||
Medical condition: Onychomycosis and associated Tinea Pedis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001430-34 | Sponsor Protocol Number: 10-TT-EP-003 | Start Date*: 2012-08-14 | |||||||||||
Sponsor Name:Deutsche Homöopathie-Union, DHU-Arzneimittel GmbH & Co. KG | |||||||||||||
Full Title: Therapeutic effectiveness, safety and tolerability of Tonsilotren tablets in patients (6 to 60 years old) with chronic tonsillitis. A randomized, international, multicenter, controlled clinical t... | |||||||||||||
Medical condition: Chronic tonsillitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002455-16 | Sponsor Protocol Number: LTGV550-PII-11/06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Laboratoires Théa | |||||||||||||
Full Title: Efficacy and safety of GV 550 in acute adenoviral keratoconjunctivitis | |||||||||||||
Medical condition: acute adenoviral keratoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001546-19 | Sponsor Protocol Number: ARGX-117-2001 | Start Date*: 2020-04-21 |
Sponsor Name:argenx BV | ||
Full Title: A First-in-Human Study in Adult Subjects Hospitalized with Covid-19 to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of ARGX-117 | ||
Medical condition: PCR-confirmed Covid-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-005493-11 | Sponsor Protocol Number: CHPAU2014/01 | Start Date*: 2015-08-31 |
Sponsor Name:Centre Hospitalier de Pau | ||
Full Title: Intrathecal Rituximab in Progressive Multiple Sclerosis | ||
Medical condition: Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005523-37 | Sponsor Protocol Number: BromCO | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:URSAPHARM Arzneimittel GmbH | |||||||||||||
Full Title: A prospective controlled proof-of-concept trial to demonstrate anti-viral effects of oral bromelaine in COVID-19 positive patients | |||||||||||||
Medical condition: Diagnosis of SARS-CoV-2 infection documented by a positive PCR test | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
